Effects of systemic β-blocker therapy on the efficacy and safety of topical brimonidine and timolol11None of the clinical investigators or authors have a proprietary interest in the products discussed in this manuscript; Pamela Barnett, Amy Batoosingh, Kuankuan Chen, Robert David, MD, Marsha Harrold, and Amanda VanDenburgh are employees of Allergan, Inc.
- 1 June 2000
- journal article
- clinical trial
- Published by Elsevier in Ophthalmology
- Vol. 107 (6) , 1171-1177
- https://doi.org/10.1016/s0161-6420(00)00081-6
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patientsAmerican Journal of Ophthalmology, 1999
- Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertensionOphthalmology, 1998
- Physicians?? Guide to Interactions Between Glaucoma and Systemic MedicationsJournal of Glaucoma, 1997
- A 1-Year Study of Brimonidine Twice Daily in Glaucoma and Ocular HypertensionArchives of Ophthalmology (1950), 1997
- Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertensionSurvey of Ophthalmology, 1996
- Systemic side effects of topical beta‐adrenergic blockersClinical Cardiology, 1996
- Effects of Brimonidine on Aqueous Humor Dynamics in Human EyesArchives of Ophthalmology (1950), 1995
- Reduced Ocular Hypotensive Effect ot Topical β-Blockers in Glaucoma Patients Receiving Oral β-BlockersJournal of Glaucoma, 1992
- Systemic drug interactions with topical glaucoma medicationsSurvey of Ophthalmology, 1990
- Interaction of Topical and Oral Timolol in GlaucomaOphthalmology, 1979